Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Projected enrollment exceeded in Miravant's phase III AMD trials

Dec. 8, 1999

Ciba Vision licenses Destiny's photodynamic therapy technology

Dec. 6, 1999

FDA advisory panel recommends approval of Visudyne therapy for wet AMD

Nov. 18, 1999

Ciba Vision introduces ocular formulation of lomefloxacin in U.K.

Nov. 15, 1999

Visudyne submitted for marketing approval in Canada

Nov. 8, 1999

Mycophenolate mofetil in the treatment of refractory uveitis

Oct. 28, 1999

AGN-192024 is better than latanoprost for lowering diurnal IOP

Oct. 28, 1999

Nonpeptide integrin antagonists from DuPont and use for inhibiting cell adhesion

Oct. 25, 1999

Alphagan safely and effectively lowers IOP in glaucoma patients

Oct. 25, 1999

News from AAO/PAAO joint meeting: droperidol may be indicated for glaucoma

Oct. 25, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...